228 related articles for article (PubMed ID: 34254473)
1. Incidence and Risk of Venous Thromboembolism in Bisphosphonates and Selective Estrogen Receptor Modulators Treatment in Korea.
Park SY; Kim SH; Kim TY; Lee YK; Ha YC; Jang S; Ahn SH; Kim HY
J Korean Med Sci; 2021 Jul; 36(27):e186. PubMed ID: 34254473
[TBL] [Abstract][Full Text] [Related]
2. Comparative risks for cancer associated with use of calcitonin, bisphosphonates or selective estrogen receptor modulators among osteoporosis patients: a population-based cohort study.
Hsiao FY; Hsu WW
Jpn J Clin Oncol; 2017 Oct; 47(10):935-941. PubMed ID: 28981741
[TBL] [Abstract][Full Text] [Related]
3. Selective estrogen receptor modulators (SERMs) with vitamin D composite agent can prevent fracture better than SERMs treatment: based on the National Health Claims Database 2017-2019.
Byun SE; Kim H; Lee SY; Kim SM
Osteoporos Int; 2024 May; 35(5):775-783. PubMed ID: 38240755
[TBL] [Abstract][Full Text] [Related]
4. Incidence and risk of venous thromboembolism among Taiwan osteoporotic fracture population under osteoporosis pharmacological treatments.
Lin TC; Lee CH; Yang CY; Yang YH; Lin SJ
J Clin Endocrinol Metab; 2014 May; 99(5):1599-607. PubMed ID: 24606074
[TBL] [Abstract][Full Text] [Related]
5. Assessment of Cardiovascular Safety of Anti-Osteoporosis Drugs.
Fuggle NR; Cooper C; Harvey NC; Al-Daghri N; Brandi ML; Bruyere O; Cano A; Dennison EM; Diez-Perez A; Kaufman JM; Palacios S; Prieto-Alhambra D; Rozenberg S; Thomas T; Tremollieres F; Rizzoli R; Kanis JA; Reginster JY
Drugs; 2020 Oct; 80(15):1537-1552. PubMed ID: 32725307
[TBL] [Abstract][Full Text] [Related]
6. [Current advances and issues in selective estrogen receptor modulator (SERM) treatment].
Ohta H
Clin Calcium; 2014 Jan; 24(1):45-52. PubMed ID: 24369279
[TBL] [Abstract][Full Text] [Related]
7. Use of oral bisphosphonates and risk of venous thromboembolism: a population-based case-control study.
Lamberg AL; Horvath-Puho E; Christensen S; Sørensen HT
Osteoporos Int; 2010 Nov; 21(11):1911-7. PubMed ID: 19997902
[TBL] [Abstract][Full Text] [Related]
8. Use of bisphosphonate and risk of atrial fibrillation in older women with osteoporosis.
Rhee CW; Lee J; Oh S; Choi NK; Park BJ
Osteoporos Int; 2012 Jan; 23(1):247-54. PubMed ID: 21431993
[TBL] [Abstract][Full Text] [Related]
9. Antiplatelet therapy use and the risk of venous thromboembolic events in the Raloxifene Use for the Heart (RUTH) trial.
Duvernoy CS; Yeo AA; Wong M; Cox DA; Kim HM
J Womens Health (Larchmt); 2010 Aug; 19(8):1459-65. PubMed ID: 20626269
[TBL] [Abstract][Full Text] [Related]
10. Risk of venous thromboembolism among users of different anti-osteoporosis drugs: a population-based cohort analysis including over 200,000 participants from Spain and the UK.
Martín-Merino E; Petersen I; Hawley S; Álvarez-Gutierrez A; Khalid S; Llorente-Garcia A; Delmestri A; Javaid MK; Van Staa TP; Judge A; Cooper C; Prieto-Alhambra D
Osteoporos Int; 2018 Feb; 29(2):467-478. PubMed ID: 29199359
[TBL] [Abstract][Full Text] [Related]
11. Use of bisphosphonates and raloxifene and risk of deep venous thromboembolism and pulmonary embolism.
Vestergaard P; Schwartz K; Pinholt EM; Rejnmark L; Mosekilde L
Osteoporos Int; 2010 Sep; 21(9):1591-7. PubMed ID: 19859641
[TBL] [Abstract][Full Text] [Related]
12. [Anti-osteoporosis drugs : their characteristics and evidence for anti-fracture efficacy].
Takeuchi Y
Clin Calcium; 2012 Jun; 22(6):897-903. PubMed ID: 22653031
[TBL] [Abstract][Full Text] [Related]
13. Pros and cons of existing treatment modalities in osteoporosis: a comparison between tibolone, SERMs and estrogen (+/-progestogen) treatments.
Kloosterboer HJ; Ederveen AG
J Steroid Biochem Mol Biol; 2002 Dec; 83(1-5):157-65. PubMed ID: 12650712
[TBL] [Abstract][Full Text] [Related]
14. Incidence and risk of venous thromboembolism according to primary treatment type in women with endometrial cancer: a population-based study.
Yuk JS; Lee B; Kim K; Kim MH; Seo YS; Hwang SO; Cho YK; Kim YB
BMC Cancer; 2021 Oct; 21(1):1166. PubMed ID: 34717579
[TBL] [Abstract][Full Text] [Related]
15. [Drug treatment of osteoporosis].
Fassbender WJ; Willmann B
Dtsch Med Wochenschr; 2014 Mar; 139(10):497-500. PubMed ID: 24570199
[No Abstract] [Full Text] [Related]
16. New selective estrogen receptor modulators (SERMs) in development.
Silverman SL
Curr Osteoporos Rep; 2010 Sep; 8(3):151-3. PubMed ID: 20603714
[TBL] [Abstract][Full Text] [Related]
17. The Association Between Long-Term Bisphosphonate Use and the Risk of Fracture Among Women Aged 50 or Older with Osteoporosis.
Wang CC; Lu HT; Dusetzina SB; Wu CH
J Womens Health (Larchmt); 2016 Jul; 25(7):738-46. PubMed ID: 27096405
[TBL] [Abstract][Full Text] [Related]
18. Incidence of and risk for osteonecrosis of the jaw in Korean osteoporosis patients treated with bisphosphonates: A nationwide cohort-study.
Kim SH; Lee YK; Kim TY; Ha YC; Jang S; Kim HY
Bone; 2021 Feb; 143():115650. PubMed ID: 32956854
[TBL] [Abstract][Full Text] [Related]
19. Association between pharmacotherapy and secondary hip fracture in a real-world setting: a nationwide database study.
Nakatoh S; Fujimori K; Ishii S; Tamaki J; Okimoto N; Ogawa S; Iki M
J Bone Miner Metab; 2023 Mar; 41(2):248-257. PubMed ID: 36853423
[TBL] [Abstract][Full Text] [Related]
20. No Increased Risk of Nonunion with Bisphosphonate Use in a Medicare Claims Cohort Following Operatively Treated Long-Bone Fractures.
Thorne TJ; Steffenson L; O'Neill DC; Marchand LS; Martin BI; Haller JM
J Bone Joint Surg Am; 2023 Apr; 105(7):549-555. PubMed ID: 36753557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
